- Home
-
Technical Platform
-
Services
- TCR-T Lead Sequence Development Service
- Immune CAR Cell Preparation Technology Service
- Antibody Coupled Drug Discovery Service
- Antibody Affinity Maturation Service
- Antibody Humanization Services
- Bispecific Antibody Development Services
- Antibody Protein Sequencing Service
- Antibody Affinity Determination Service
Antibody Drugability Assessment
- Aptamer-Drug Conjugate (ApDC) Development Services
- Nuclide Nucleic Acid Aptamer Screening Service
- Nucleic Acid Aptamer Synthesis Service
- Nucleic Acid Aptamer Modification Service
- Nucleic Acid Aptamer Library Construction Service
- Bispecific Aptamer Development Service
- Protein Nucleic Acid Aptamer Screening Service
- Metal Ion Nucleic Acid Aptamer Screening Service
- Small Molecule Nucleic Acid Aptamer Screening Service
- Cell Nucleic Acid Aptamer Screening Service
- Peptide Affinity Maturation Services
- Peptide-Drug Conjugate (PDC) Development Services
- Stapled Peptide Development Services
- Targeted Peptide Library Screening Service
- Targeted Peptide Library Construction Service
Active Peptide Discovery Technology Service
- mRNA Antibody Production Services
- mRNA Immunogen Production Service
- DNA Immune Antibody Preparation Service
Animal Immunization Technology Services
-
Technical Support
- Structural Basis for Selectivity and Antagonism in GPCR-Nanobodies
- Novel Peptide-Drug Conjugate (PDC) Shows Efficacy in Hepatocellular Carcinoma Models
- Nanobody Expression in Insect Cells
- Nanobody Mammalian Cell Expression
- Single-chain Antibody Library Construction Technology Introduction
- Prokaryotic Expression of Nanobodies
- Cell Line Immunogen of Nanobody
- Construction of Single Chain Antibody Library
- Nano-antibody/Single Domain Antibody Library Construction Service
- Customized Nano-antibody Immunogen3
- Recombinant Expression Strategies for Bispecific Antibodies: What You Need to Know？
- Antibody Engineering and Modification: Maximizing Therapeutic and Diagnostic Utility
- Bispecific Antibodies (bsAbs): Mechanisms of Action Explained
- Applications of bispecific antibodies in cancer therapy
- Beyond PD-1 Blockade: How BiCE Bridges T Cells and cDC1s to Unlock Cold Tumors
- From Purity to Functionality: A Comprehensive Guide to Recombinant Antibody Quality Control Standards
- How much do you know about the molecular design and mechanism of action of ADC drugs?
- The ADC linker serves as a crucial "bridge" component.
- ADCs are becoming increasingly mature in the field of tumor therapy.
- Cracking the Immune System’s “Source Code”: Why Is B-Cell Technology the Ultimate Path to Antibody Discovery?
Special topic on antibody modification
- High-Throughput Yeast Display Platform for Macrocyclic Peptide Discovery
- How Are Antibody Drugs Produced? A Deep Dive into Mammalian Cell Culture and Purification Processes
- Expression of Recombinant Antibodies in Mammalian Cells: Core Technologies – Comprehensive Analysis of Host Selection and Purification Strategies
- Bacteriophages, yeast, mRNA display: Who is the champion of the display technology?
- Breakthrough: Ultra-High Sensitivity Detection of Legionella Using an Aptamer-Based Electrochemical Sensor
- Construction of yeast hybrid library: Gateway technology
- Eukaryotic System-Based Targeted Drug Discovery Platform: Yeast Display Technology
- Common Problems and Solutions for Yeast Two-hybrid Experiments
- Yeast Two-hybrid Technique Related Issues
- Common Problems and Solutions of Yeast Display Technology
Yeast Display Technology Special Topic
- Stop Sticking with Hybridoma! A Primer on the Three Generations of Antibody Discovery Technology
- Rationale and Significance of Bispecific Antibody Development
- Protein Not Expressing? You Might Have Chosen the Wrong Tag!
- What to Do After Protein Purification? These Four Validation Methods You Must Know!
- Yeast Two-Hybrid Technology Reveals a Novel Mechanism of Wheat Disease Resistance: How TaPIR1 "Hijacks" TaHRP1 to Suppress Chloroplast Function?
- Yeast Hybrid Library Construction: Smart Technology
- New Molecular Interaction Technology: How Much Do You Know About Yeast Hybridization Technology?
- Antibody Affinity Testing(SPR)
- Hybridoma Gene Sequencing Process
- Antibody Affinity Detection (BLI)
Antibody Detection Service Topic
- Frontiers in Targeted Drug Development: Comparison and Application of Various Peptide Screening Methods
- Application of phage display (Part 2)
- Application of phage display (Part 1)
- Phage Display
- Technical Article: Detailed Guide to Phage Screening
- Frontiers in Targeted Drug Development: Comparison and Application of Multiple Peptide Screening Methods
- Revolutionary Advances in Single-Domain Antibody Development and Applications
- New Method for Discovering Targeted Drugs: Screening of Peptide Libraries Based on Phage Display Technology
- How much do you know about IgG, Fab, scFv, and VHH?
- Novel Targeted Tumor Therapeutics: Efficacy of a Peptide-Drug Conjugate (PDC) in a Hepatocellular Carcinoma Model
Special Topic on Phage Display Technology
- CD7-targeted Antibody-Drug Conjugates: A New Hope for T-Cell Acute Lymphoblastic Leukemia
- Discovery of targeted nucleic acid small molecules: Cell-SELEX technology
- A Promising Novel Cancer Therapeutic Strategy: Aptamer-Drug Conjugates (ApDCs)
- A Novel Therapeutic Approach for Multiple Myeloma: Development of a CD38 and CD47 Bispecific Bipartopic Antibody
- A Novel Therapeutic Approach - CAR-M
- Application And Prospects of CAR-T Technology in Tumor Immunotherapy
- CAR-T Discovery Service
CAR-T Molecule Discovery Topic
- In Vivo Screening Services – Animal Models
- The Promise of Small Nucleic Acid Therapeutics: From Bench to Clinic as Next-Generation Medicines
- Issues Related to Aptamer Library Screening
- Introduction to Nucleic Acid Aptamer Library Screening Technology
- Overview of Aptamer Synthesis Technology
- Screening and optimization of nucleic acid aptamers
- Screening and Application of Peptide Aptamers
- Main Research Directions Progress and Challenges of Nucleic Acid Aptamer Screening Technology
- Research Progress of Protein Nucleic Acid Aptamer Screening
- Research Progress of Aptamer Screening-of Small Molecule Targets
Molecular Biology Service Topics
-
Product Center
- Contact Us
Review of vascular homing peptides for tumor nanomedicine. Covers targets, phage display discovery, advantages & limitations. Despite <1% NP tumor accumulation, peptides enhance specificity, penetration & reduce toxicity.
This study presents DGCR2-specific Affibody binder ZDGCR2:AM106 with nanomolar affinity, high stability, and renal clearance, enabling targeted delivery of therapeutics and imaging probes to pancreatic β-cells for diabetes research.
Detailed insight into a novel yeast display method using a Cys-free GPI anchor to prevent disulfide mismatching. Learn how FACS normalization and yeast surface titration enable direct KD measurement without chemical synthesis.
Explore key BsAb expression strategies: Knobs-into-Holes, Common Light Chain, bidirectional promoters, and alkali-resistant Protein L. Learn how to overcome chain mispairing and boost yield.
Natural antibodies are not inherently perfect. Expression of an antibody is merely the first step; it is typically followed by engineering and chemical modification to maximize its efficacy for specific downstream applications.
Explore the mechanisms of action of bispecific antibodies (bsAbs): combinatorial and obligatory modes, T-cell engagers, dual pathway blockade, and Fc engineering. Learn how bsAbs overcome drug resistance and reshape cancer immunotherapy.\n
Drug absorption, distribution, metabolism, and excretion cannot be fully simulated in vitro. This article provides an in-depth analysis of how in vivo screening offers a comprehensive, panoramic evaluation of drug efficacy and safety, highlighting the applications of mouse and zebrafish disease models.
Leveraging cutting-edge bsAbs mechanisms for cancer therapy—including dual signaling modulation, T-cell engagers (BiTE), immune checkpoint inhibition, costimulatory receptor activation, and bispecific ADCs—Taike Biotech offers one-stop services from lead candidate discovery (phage/yeast display), bsAb design and construction, in vitro functional validation, to in vivo efficacy evaluation, accelerating your next-generation immuno-oncology drug development.
BiCE enhances T cell–cDC1 conjugation, expands cDC1 pools, and synergizes with aCD40 to suppress tumor growth in PD-1-unresponsive models, redefining bispecific immunotherapy strategies
How to evaluate recombinant antibody quality? Purity, specificity, affinity, functionality, and more. Tek Biotech offers expert QC and expression services.
